{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-325243","form_type":"8-K","ticker":"WHWK","cik":"0001422142","company_name":"Whitehawk Therapeutics, Inc.","filed_at":"2021-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.488823+00:00","generated_at":"2026-06-28T09:48:45.529211+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aadi Q3 net loss $87.2M; FYARRO PDUFA Nov 26; cash $161.4M","bullets":["FYARRO (nab-sirolimus) NDA under FDA priority review with PDUFA target Nov 26, 2021.","Ended Q3 with $161.4M cash; expected runway into 2024 post merger & $155M PIPE.","Net loss $87.2M for Q3, primarily from $74.2M non-cash impairment related to merger.","Appointed Brendan Delaney COO, Loretta Itri CMO (Q4), Scott Giacobello CFO (Nov 28).","Plan to initiate registrational trial in TSC1/TSC2 tumors by end 2021 or early 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-325243","json":"https://secwatch.observer/filing/0001193125-21-325243.json","markdown":"https://secwatch.observer/filing/0001193125-21-325243.md","text":"https://secwatch.observer/filing/0001193125-21-325243.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422142/000119312521325243/0001193125-21-325243-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422142/000119312521325243/d249085d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T09:48:45.529211+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}